A Phase 3 interventional study of VGX-3100 and Placebo in Cervical Dysplasia, Cervical High Grade Squamous Intraepithelial Lesion and HSIL, sponsored by Inovio Pharmaceuticals. Completed at 60 sites in 19 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-27.
Sponsored by Inovio Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 109 studies in Uterine Cervical Dysplasia with a site in United States — 10 open to participants now, 14 under way, none of them phase 3. Uterine Cervical Dysplasia · United States.
Among the 109 studies in Uterine Cervical Dysplasia with a site in United States, this one is the 26th largest by enrollment of the 86 interventional ones that give a count, is one of 5 that started in 2017, is one of 12 in phase 3, and was the 81st registered.
409 studies on the registry are indexed under Uterine Cervical Dysplasia; 76 are open to participants now.
Browse Uterine Cervical Dysplasia studies →10 of the 109 studies in Uterine Cervical Dysplasia with a site in United States are open now. Recruiting first, the newest first:
PapiVax Biotech, Inc. · Sites in United States, Taiwan
Ages 18–60 · Women only
Lindsay Ferguson, MD · Sites in United States
Ages 18+ · Women only
Louisiana State University Health Sciences Center in New Orleans · Sites in United States
Ages 18–65 · Healthy volunteers
Northwell Health · Sites in United States
Ages 18+ · Women only
Mayo Clinic · Sites in United States
Ages 18+ · Women only
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 43 Uterine Cervical Dysplasia studies recruiting now, 19 (44%) set no upper age limit and 21 (49%) stop at 75 or younger; 3 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
109 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 18 · Phase 2 31 · Phase 3 14 · Phase 4 2
First in 1993; this study’s year is marked. 5 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 201 is above the median of 167 across 285 interventional studies indexed under Uterine Cervical Dysplasia.
Median enrollment 80 across the 86 interventional studies, 250 across the 21 observational. Of the 83 that completed or were terminated, 27 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 109 have an industry lead sponsor. The 10 most frequent:
Inovio Pharmaceuticals is the lead sponsor of 31 studies on the registry; none are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 10 (71%) have results posted.
Inovio Pharmaceuticals has 3 studies filed under Uterine Cervical Dysplasia — fewer than ten, so there is no comparison to draw.
4 of the studies in Uterine Cervical Dysplasia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06191133Lindsay Ferguson, MDFenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma | 2026-12-30 |
| NCT04712851Jonsson Comprehensive Cancer CenterPembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia | 2027-01-31 |
| NCT05051722Mayo ClinicLeveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer | 2027-07-30 |
| NCT07520188UNC Lineberger Comprehensive Cancer CenterC-3002: Enhancing Cervical Cancer Screening Access and Follow-up Care at 'CASCADE' Clinical Sites in the United States | 2027-10-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 109 studies in Uterine Cervical Dysplasia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
HPV-301 is a prospective, randomized, double-blind, placebo controlled Phase 3 study to determine the efficacy, safety, and tolerability of VGX-3100 administered by intramuscular (IM) injection followed by electroporation (EP) delivered with CELLECTRA™ 5PSP in adult women with histologically confirmed cervical high grade squamous intraepithelial lesion (HSIL) (cervical intraepithelial neoplasia grade 2 [CIN2] or grade 3 [CIN3]) associated with human papillomavirus (HPV) 16 and/or HPV-18.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received three IM injections of 6 milligram (mg) (in 1 milliliter \[mL\]) VGX-3100 followed by EP using the CELLECTRA™-5PSP device on Day 0, Week 4, and Week 12.
Biological: VGX-3100 · Device: Electroporation (EP)
Participants received three IM injections of 1 mL VGX-3100 matching placebo followed by EP using the CELLECTRA™-5PSP device on Day 0, Week 4, and Week 12.
Biological: Placebo · Device: Electroporation (EP)
1 mL VGX-3100 will be injected IM and delivered by EP using CELLECTRA™-5PSP on Day 0, Week 4 and Week 12.
1 mL of Placebo will be injected IM and delivered by EP using CELLECTRA™-5PSP on Day 0, Week 4 and Week 12.
Intramuscular injection followed by EP with the CELLECTRA™ 5PSP device.
Percentage of Participants With No Evidence of Cervical HSIL on Histology and No Evidence of HPV-16 and/or HPV-18 in Cervical Samples
Participants with no histologic (i.e., biopsies or excisional treatment) evidence of cervical HSIL, no evidence of HPV-16 and/or HPV-18 at the Week 36 time frame, and participants in which excision or biopsy sample was not obtained between the initial dose up to Week 36 were considered to be responders. No evidence of HSIL was defined by histology as negative, squamous atypia, or low-grade intraepithelial lesion (LSIL). Cervical samples for HPV-16 and/or HPV-18 were collected using the ThinPrep®.
Time frame: Week 36
Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs) Following Investigational Treatment for the Duration of the Study
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as AEs. An SAE is any experience that suggested a significant hazard, contraindication, side effect, or precaution, and fulfilled any of the following criteria: fatal (resulted in death), life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was medically significant or required intervention to prevent any of the other outcomes listed here.
Time frame: From baseline up to Week 88
Percentage of Participants With No Evidence of Cervical HSIL on Histology
Participants with no histologic (i.e., biopsies or excisional treatment) evidence of cervical HSIL at Week 36 and participants in which an excision or biopsy sample was not obtained between the initial dose up to Week 36 were considered to be responders. No evidence of HSIL was defined by histology as negative, squamous atypia, or LSIL.
Time frame: Week 36
Percentage of Participants With No Evidence of HPV-16 and/or HPV-18 in Cervical Samples by Type Specific HPV Testing
Participants with no evidence of HPV-16 and/or HPV-18 at the Week 36 time frame and participants in which an excision or biopsy sample was not obtained between the initial dose up to Week 36 were considered to be responders. Cervical samples for HPV-16 and/or HPV-18 were collected using the ThinPrep®.
Time frame: Week 36
Percentage of Participants With No Evidence of LSIL or HSIL on Histology
Participants with no histologic evidence of cervical HSIL, squamous atypia, or LSIL at the Week 36 time frame and participants in which an excision or biopsy sample was not obtained between the initial dose up to Week 36 were considered to be responders. No evidence of HSIL was defined as no evidence of cervical squamous intraepithelial neoplasia 1 (CIN1), CIN2, or CIN3 on biopsies or excisional treatment.
Time frame: Week 36
Percentage of Participants With No Evidence of LSIL or HSIL and No Evidence of HPV-16 and/or HPV-18
Participants with no histologic evidence of cervical HSIL, squamous atypia, and LSIL, no evidence of HPV-16 and/or HPV-18 by type specific HPV testing at the Week 36 time, and participants in which an excision or biopsy sample was not obtained between initial dose up to Week 36 were considered to be responders. No evidence of HSIL was defined as no evidence of CIN1, CIN2, or CIN3 on biopsies or excisional treatment.
Time frame: Week 36
Percentage of Participants With No Progression of Cervical HSIL to Cervical Carcinoma
Participants with no histologic evidence of cervical Adenocarcinoma in situ or cervical carcinoma at the Week 36 timeframe relative to baseline and participants in which an excision or biopsy sample was not obtained between initial dose up to Week 36 were considered as responders.
Time frame: Week 36
Percentage of Participants Who Have Cleared HPV-16 and/or HPV-18 in Non-cervical Anatomic Locations
Participants with no evidence of HPV-16 and/or HPV-18 on specimens from noncervical anatomic locations (oropharynx, vagina and intra-anal) at the Week 36 time frame were considered as responder.
Time frame: Week 36
Levels of Serum Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations
A standardized binding enzyme-linked immunosorbent assay (ELISA) was performed to measure the anti-HPV-16/18 antibody response induced by VGX-3100.
Time frame: Week 15 and Week 36
Change From Baseline in Interferon-Gamma Response Magnitude
Assessment of cellular immune activity occurred via the application of the Interferon-γ enzyme-linked immunosorbent spot (IFN-γ ELISpot). Peripheral blood mononuclear cells (PBMCs) isolated from whole blood sample were used for analysis.
Time frame: Baseline; Week 15 and Week 36
Change From Baseline in Flow Cytometry Response Magnitude
Assessment of cellular immune activity was measured using the application flow cytometry for the purposes of performing a Lytic Granule Loading Assay. The Lytic Granule Loading assay examines the following external cellular markers: CD3, CD4, CD8 (T cell identification), CD137, CD38 and CD69 (T cell activation markers) as well as PD-1 (exhaustion/activation marker). Here change from baseline in CD8+CD137+Perforin+, CD8+CD38+Perforin+ and CD8+CD69+Perforin+ are reported.
Time frame: Baseline, Week 15
Participants took part in the study at 96 study centers in 20 countries from 28 June 2017 to 6 April 2021.
| Milestone | VGX-3100 + Electroporation (EP) | Placebo + EP |
|---|---|---|
| Started | 138 | 63 |
| Intent-to-treat (itt) population | 138 | 63 |
| Modified itt (mitt) population | 134 | 63 |
| Safety population | 136 | 63 |
| Completed | 116 | 56 |
| Not completed | 22 | 7 |
| Withdrew: Withdrawal by subject | 5 | 3 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Progressive disease | 1 | 0 |
| Withdrew: Lost to follow-up | 8 | 2 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Protocol deviation | 2 | 0 |
| Withdrew: Reason not specified | 3 | 2 |
| Withdrew: Death | 1 | 0 |
Participants with no histologic (i.e., biopsies or excisional treatment) evidence of cervical HSIL, no evidence of HPV-16 and/or HPV-18 at the Week 36 time frame, and participants in which excision or biopsy sample was not obtained between the initial dose up to Week 36 were considered to be responders. No evidence of HSIL was defined by histology as negative, squamous atypia, or low-grade intraepithelial lesion (LSIL). Cervical samples for HPV-16 and/or HPV-18 were collected using the ThinPrep®.
| percentage of participants | VGX-3100 + Electroporation (EP) | Placebo + EP |
|---|---|---|
| Percentage of Participants With No Evidence of Cervical HSIL on Histology and No Evidence of HPV-16 and/or HPV-18 in Cervical Samples | 22.5 | 11.1 |
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as AEs. An SAE is any experience that suggested a significant hazard, contraindication, side effect, or precaution, and fulfilled any of the following criteria: fatal (resulted in death), life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was medically significant or required intervention to prevent any of the other outcomes listed here.
| Participants | VGX-3100 + Electroporation (EP) | Placebo + EP |
|---|---|---|
| Number of Participants with any AE | 131 | 61 |
| Number of Participants with any SAE | 13 | 6 |
Participants with no histologic (i.e., biopsies or excisional treatment) evidence of cervical HSIL at Week 36 and participants in which an excision or biopsy sample was not obtained between the initial dose up to Week 36 were considered to be responders. No evidence of HSIL was defined by histology as negative, squamous atypia, or LSIL.
| percentage of participants | VGX-3100 + Electroporation (EP) | Placebo + EP |
|---|---|---|
| Percentage of Participants With No Evidence of Cervical HSIL on Histology | 31.9 | 19.0 |
Participants with no evidence of HPV-16 and/or HPV-18 at the Week 36 time frame and participants in which an excision or biopsy sample was not obtained between the initial dose up to Week 36 were considered to be responders. Cervical samples for HPV-16 and/or HPV-18 were collected using the ThinPrep®.
| percentage of participants | VGX-3100 + Electroporation (EP) | Placebo + EP |
|---|---|---|
| Percentage of Participants With No Evidence of HPV-16 and/or HPV-18 in Cervical Samples by Type Specific HPV Testing | 34.1 | 15.9 |
Participants with no histologic evidence of cervical HSIL, squamous atypia, or LSIL at the Week 36 time frame and participants in which an excision or biopsy sample was not obtained between the initial dose up to Week 36 were considered to be responders. No evidence of HSIL was defined as no evidence of cervical squamous intraepithelial neoplasia 1 (CIN1), CIN2, or CIN3 on biopsies or excisional treatment.
| percentage of participants | VGX-3100 + Electroporation (EP) | Placebo + EP |
|---|---|---|
| Percentage of Participants With No Evidence of LSIL or HSIL on Histology | 24.6 | 11.1 |
Participants with no histologic evidence of cervical HSIL, squamous atypia, and LSIL, no evidence of HPV-16 and/or HPV-18 by type specific HPV testing at the Week 36 time, and participants in which an excision or biopsy sample was not obtained between initial dose up to Week 36 were considered to be responders. No evidence of HSIL was defined as no evidence of CIN1, CIN2, or CIN3 on biopsies or excisional treatment.
| percentage of participants | VGX-3100 + Electroporation (EP) | Placebo + EP |
|---|---|---|
| Percentage of Participants With No Evidence of LSIL or HSIL and No Evidence of HPV-16 and/or HPV-18 | 18.1 | 6.3 |
Participants with no histologic evidence of cervical Adenocarcinoma in situ or cervical carcinoma at the Week 36 timeframe relative to baseline and participants in which an excision or biopsy sample was not obtained between initial dose up to Week 36 were considered as responders.
| percentage of participants | VGX-3100 + Electroporation (EP) | Placebo + EP |
|---|---|---|
| Percentage of Participants With No Progression of Cervical HSIL to Cervical Carcinoma | 84.1 | 85.7 |
Participants with no evidence of HPV-16 and/or HPV-18 on specimens from noncervical anatomic locations (oropharynx, vagina and intra-anal) at the Week 36 time frame were considered as responder.
| percentage of participants | VGX-3100 + Electroporation (EP) | Placebo + EP |
|---|---|---|
| Percentage of Participants Who Have Cleared HPV-16 and/or HPV-18 in Non-cervical Anatomic Locations | 20.3 | 9.5 |
A standardized binding enzyme-linked immunosorbent assay (ELISA) was performed to measure the anti-HPV-16/18 antibody response induced by VGX-3100.
| reciprocal endpoint titer | VGX-3100 + Electroporation (EP) | Placebo + EP |
|---|---|---|
| HPV-16 E7 at Week 15 | 225.0 (1 to 18225) | 1.0 (1 to 6075) |
| HPV-16 E7 at Week 36 | 1.0 (1 to 18225) | 1.0 (1 to 6075) |
| HPV-18 E7 at Week 15 | 2025.0 (1 to 18225) | 1.0 (1 to 18225) |
| HPV-18 E7 at Week 36 | 225.0 (1 to 18225) | 1.0 (1 to 2025) |
Assessment of cellular immune activity occurred via the application of the Interferon-γ enzyme-linked immunosorbent spot (IFN-γ ELISpot). Peripheral blood mononuclear cells (PBMCs) isolated from whole blood sample were used for analysis.
| spot forming units (SFU)/10^6 PBMC | VGX-3100 + Electroporation (EP) | Placebo + EP |
|---|---|---|
| HPV-16 E6: Baseline | 0.83 (0.0 to 40.0) | 0.00 (0.0 to 16.7) |
| HPV-16 E6: Change from Baseline at Week 15 | 13.33 (0.0 to 446.7) | 0.00 (0.0 to 13.3) |
| HPV-16 E6: Change from Baseline at Week 36 | 8.33 (0.0 to 780.0) | 0.00 (0.0 to 25.0) |
| HPV-16 E7: Baseline | 0.00 (0.0 to 53.3) | 0.00 (0.0 to 83.3) |
| HPV-16 E7: Change from Baseline at Week 15 | 10.83 (0.0 to 213.3) | 0.00 (0.0 to 13.3) |
| HPV-16 E7: Change from Baseline at Week 36 | 7.50 (0.0 to 81.7) | 0.00 (0.0 to 8.3) |
| HPV-18 E6: Baseline | 0.00 (0.0 to 10.0) | 0.00 (0.0 to 20.0) |
| HPV-18 E6: Change from Baseline at Week 15 | 50.83 (0.0 to 1910.0) | 0.00 (0.0 to 6.7) |
| HPV-18 E6: Change from Baseline at Week 36 | 38.33 (0.0 to 1031.7) | 0.0 (0.0 to 23.3) |
| HPV-18 E7: Baseline | 0.00 (0.0 to 11.7) | 0.00 (0.0 to 91.7) |
| HPV-18 E7: Change from Baseline at Week 15 | 14.17 (0.0 to 251.7) | 0.00 (0.0 to 20.0) |
| HPV-18 E7: Change from Baseline at Week 36 | 10.00 (0.0 to 508.3) | 0.00 (0.0 to 6.7) |
Assessment of cellular immune activity was measured using the application flow cytometry for the purposes of performing a Lytic Granule Loading Assay. The Lytic Granule Loading assay examines the following external cellular markers: CD3, CD4, CD8 (T cell identification), CD137, CD38 and CD69 (T cell activation markers) as well as PD-1 (exhaustion/activation marker). Here change from baseline in CD8+CD137+Perforin+, CD8+CD38+Perforin+ and CD8+CD69+Perforin+ are reported.
| SFU/10^6 PBMC | VGX-3100 + Electroporation (EP) | Placebo + EP |
|---|---|---|
| CD8+CD137+Perforin+: Baseline | 0.004 (0.00 to 0.15) | 0.001 (0.00 to 0.22) |
| CD8+CD137+Perforin+: Change from Baseline at Week 15 | 0.035 (0.00 to 0.44) | 0.000 (0.00 to 0.10) |
| CD8+CD38+Perforin+: Baseline | 0.000 (0.00 to 0.21) | 0.000 (0.00 to 0.12) |
| CD8+CD38+Perforin+: Change from Baseline at Week 15 | 0.011 (0.00 to 0.23) | 0.000 (0.00 to 0.10) |
| CD8+CD69+Perforin+: Baseline | 0.009 (0.00 to 0.11) | 0.001 (0.00 to 0.13) |
| CD8+CD69+Perforin+: Change from Baseline at Week 15 | 0.044 (0.00 to 0.37) | 0.000 (0.00 to 0.07) |
Collected over From baseline up to Week 88. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| VGX-3100 + Electroporation (EP) | 1/136 (0.7%) | 13/136 (9.6%) | 131/136 (96.3%) |
| Placebo + EP | 0/62 (0%) | 6/62 (9.7%) | 61/62 (98.4%) |
| Event | VGX-3100 + Electroporation (EP) | Placebo + EP |
|---|---|---|
| Squamous Cell Carcinoma of the CervixNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 5/136 | 0/62 |
| Cervix CarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/136 | 2/62 |
| Adenosquamous Carcinoma of the CervixNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/136 | 1/62 |
| Upper Limb FractureInjury, poisoning and procedural complications | 0/136 | 1/62 |
| Abortion SpontaneousPregnancy, puerperium and perinatal conditions | 0/136 | 1/62 |
| Ectopic PregnancyPregnancy, puerperium and perinatal conditions | 0/136 | 1/62 |
| Vaginal HaemorrhageReproductive system and breast disorders | 0/136 | 1/62 |
| Ligament InjuryInjury, poisoning and procedural complications | 1/136 | 0/62 |
| Diaphragmatic HerniaGastrointestinal disorders | 1/136 | 0/62 |
| Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders | 1/136 | 0/62 |
| Event | VGX-3100 + Electroporation (EP) | Placebo + EP |
|---|---|---|
| Injection Site PainGeneral disorders | 105/136 | 49/62 |
| HeadacheNervous system disorders | 46/136 | 19/62 |
| FatigueGeneral disorders | 40/136 | 18/62 |
| Injection Site PruritusGeneral disorders | 34/136 | 14/62 |
| Injection Site ErythemaGeneral disorders | 33/136 | 14/62 |
| Injection Site SwellingGeneral disorders | 28/136 | 15/62 |
| MyalgiaMusculoskeletal and connective tissue disorders | 28/136 | 14/62 |
| NauseaGastrointestinal disorders | 25/136 | 11/62 |
| Injection Site BruisingGeneral disorders | 14/136 | 9/62 |
| Injection Site HaematomaGeneral disorders | 8/136 | 6/62 |
ITT population included all participants who were randomized.
| Age, Continuous(years) | VGX-3100 + Electroporation (EP) | Placebo + EP | Total |
|---|---|---|---|
| Mean | 31.3 ± 6.53 | 31.9 ± 6.08 | 31.5 ± 6.38 |
| Sex: Female, Male(Participants) | VGX-3100 + Electroporation (EP) | Placebo + EP | Total |
|---|---|---|---|
| Female | 138 | 63 | 201 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | VGX-3100 + Electroporation (EP) | Placebo + EP | Total |
|---|---|---|---|
| Hispanic or Latino | 22 | 9 | 31 |
| Not Hispanic or Latino | 112 | 54 | 166 |
| Unknown or Not Reported | 4 | 0 | 4 |
| Race/Ethnicity, Customized(Participants) | VGX-3100 + Electroporation (EP) | Placebo + EP | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 9 | 6 | 15 |
| Black or African American | 8 | 5 | 13 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| White | 109 | 46 | 155 |
| Other | 10 | 2 | 12 |
| Multiple | 1 | 0 | 1 |
| Missing | 1 | 2 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jun 2017 to primary completion in Jul 2020, 36 months.
Results were first posted in Jul 2023, 3 years after primary completion. A results delay was requested in Jul 2021.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: VGX-3100